Dossier: Diabetes: Basic Research and Clinical ApproachEfficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients
Introduction
According to the World Health Organization (WHO), 10–15% of all European men and 15–25% of all European women are obese and the problem of overweight has been extending gradually, turning obesity into one of the leading mortality causes worldwide [1], [2], [3], [4], [5]. Furthermore, obesity is a well-known risk factor for the metabolic syndrome [6], type 2 diabetes mellitus [6], [7], coronary heart disease [8] and stroke [9]. Even moderate weight reduction of 5–10% has been shown to significantly improve the majority of these risk factors [10], [11]. Even though lifestyle modifications including diet and exercise regimens are still considered the cornerstones of obesity management; in a considerable number of patients these approaches are of limited success. Pharmacological agents can be useful adjuncts to exercise and dietary therapy, especially when associated metabolic and vascular risk factors justify aggressive weight management interventions for the patient [12]. In recent years, several new oral pharmacological agents with different acting mechanisms have been introduced for the purpose of antiobesity therapy. Sibutramine hydrochloride is a central acting serotonin and noradrenalin reuptake-inhibitor (SNRI) with weight reducing properties [13]. Although its mechanisms of action are not fully clear yet [14], sibutramine is said to execute its effect via a dual action of enhancing satiety and increasing energy expenditure by enhancing metabolic rate [13]. Orlistat, the first agent in the lipase inhibitor class of antiobesity drugs [15], has a peripheral, selective inhibitory acting mechanism on gastric and pancreatic lipases, leading to a dose dependant reduction in dietary fat absorption [16], with a maximum of 30% [17]. Although many studies have been focusing on the efficacy and safety of either sibutramine or orlistat alone in contrast to placebo, very little is known about comparison of the performance of these drugs, as well as the effects of combining sibutramine and orlistat. The aim of this study was to compare the efficacy of sibutramine and orlistat, in mono- and combination therapy, with the effect of non-pharmaceutical therapy on BMI of obese patients. Furthermore, adverse effects in the four different interventional groups were monitored.
Section snippets
Materials and methods
The local ethical committee approved the study protocol. The study was carried out in accordance with the Declaration of Helsinki with all patients giving their informed consent.
The study was designed as a prospective, short-term, open-labeled randomized trial and conducted at a hospital internal medicine outpatient clinic unit. The follow-up period was 3 months. Inclusion criteria were age over 18 and under 60 years, history of at least one unsuccessful attempt to lose weight by dietary
Results
Demographic and baseline clinical characteristics of the study population are shown in Table 1. There was no statistically significant difference between the groups concerning baseline demographic and main outcome parameters. Eighty-six of a total of 104 initially enrolled patients completed the study with a drop out rate of 17.30% mainly because of failure to attend the clinical appointments. There was only one case in the combination therapy group, with allergic side effects occurring 1 h
Discussion
In our study, we aimed at comparing the effects of two oral antiobesity drugs, sibutramine and orlistat and their combination, on obesity in contrast to a non-pharmaceutical approach with calorie-restricted diet and exercise regimen, which turned out to be least effective on weight loss and BMI decrease, producing statistically significant differences with all other interventional groups. These results are in accordance with many randomized controlled trials, conducted with either of the two
Conclusion
According to our study results, compared to pharmaceutical intervention, diet and exercise regimen were significantly less effective in terms of weight loss and BMI decrease in short-term obesity management. When comparing efficacy of mono-therapy of the two drugs, sibutramine proved to be more effective in terms of weight management than orlistat. Combination therapy was more effective than orlistat mono-therapy, but showed no superior effect compared to sibutramine mono-therapy. Although the
Acknowledgements
The authors wish to express their gratitude to Dr Richard Atkinson (University of Wisconsin Medical School, Beers-Murphy Clinical Nutrition Center), Dr Hans Hauner (German Diabetes Research Institute, Heinrich-Heine-University Duesseldorf), Dr D. De Zeeuw, Dr R.H. Henning and Dr Y.E. Kocabasoglu (University of Groeningen, Faculty of Medicine, Department of Clinical Pharmacology) for their valuable suggestions and critically reading the manuscript.
References (33)
- et al.
effects of sibutramine on weight maintenance after weight loss: a randomized trial
Lancet
(2000) - et al.
Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine
Am. J. Med.
(1999) - et al.
Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicenter Orlistat Study Group
Lancet
(1998) Epidemiology; definition and classification of obesity
- World Health Organization 1990 Report of the WHO Study Group: diet, nutrition and prevention of chronic diseases,...
Worldwide epidemiology of obesity
Pharmacoeconomics
(1994)obesity epidemic puts millions at risk from related diseases
Press Release WHO
(1997)Int. J. Epidemiol.
(1989)The role of obesity in diabetes
Int. J. Obes.
(1992)- et al.
Weight as a risk factor for clinical diabetes in women
Am. J. Epidemiol.
(1990)
Obesity as independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study
Circulation
A prospective study of body mass index, weight change and risk of stroke in women
JAMA
Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal/visceral fat reduction?
Int. J. Obes.
Confronting the failure of behavioural and dietary treatments of obesity
Clin. Psychol. Rev.
Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study
Int. J. Obes.
Cited by (58)
Effects of acute low-dose combined treatment with rimonabant and sibutramine on appetite and weight gain in rats
2010, Pharmacology Biochemistry and BehaviorSibutramine & naloxone: Infra-additive interaction in the regulation of appetite?
2010, Behavioural Brain ResearchToxicity of sibutramine hydrochloride-adulterated weight loss supplements in rats based on biochemical and organ weight parameters
2024, Journal of Pharmacy and Pharmacognosy ResearchRole of orlistat combined with life style in the management of obese patients with polycystic ovarian syndrome
2018, Pakistan Journal of Medical and Health Sciences